Biocryst Pharmaceuticals (BCRX) Enterprise Value (2010 - 2026)

Biocryst Pharmaceuticals' Enterprise Value history runs 17 years deep, the most recent figure standing at -$67.7 million for Q1 2026.

• Quarterly Enterprise Value rose 64.42% year-over-year to -$67.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$67.7 million (up 64.42% YoY) and the FY2025 annual result came in at -$185.2 million, up 42.27% from the prior year.
• Enterprise Value was -$67.7 million for Q1 2026 at Biocryst Pharmaceuticals, up from -$185.2 million in the prior quarter.
• Across five years, Enterprise Value topped out at -$67.7 million in Q1 2026 and bottomed at -$443.5 million in Q1 2022.
• A 5-year average of -$277.2 million and a median of -$248.3 million in 2023 frame the typical range for Enterprise Value.
• Peak annual rise in Enterprise Value reached 76.16% in 2022, while the deepest fall reached 2439.62% in 2022.
• Biocryst Pharmaceuticals' Enterprise Value stood at -$121.0 million in 2022, then sank by 221.44% to -$389.0 million in 2023, then climbed by 17.52% to -$320.8 million in 2024, then jumped by 42.27% to -$185.2 million in 2025, then surged by 63.47% to -$67.7 million in 2026.
• Business Quant data shows BCRX's Enterprise Value at -$67.7 million in Q1 2026, -$185.2 million in Q4 2025, and -$212.9 million in Q3 2025.